NMRA

Neumora Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↑ 6/10
  • Value↓ 4/10
Neumora Therapeutics sales and earnings growth
NMRA Growth
Good
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 17.39%
  • FCF Y/Y↓ 3.17%
Neumora Therapeutics gross and profit margin trends
NMRA Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 0.00%
Neumora Therapeutics net debt vs free cash flow
NMRA Risk
Great
  • Debt / Equity↓ 0.8
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -46.9

Neumora Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks